Protalix BioTherapeutics, Inc. Net Income Loss

• Protalix BioTherapeutics, Inc. showed a decrease of -325.2% in Net Income Loss from 2024 to 2025.
• This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Protalix BioTherapeutics, Inc.'s Net Income Loss has grown by 79.0%.
• Historical annual values: Fiscal year 2025: -$6.60 million | Fiscal year 2024: $2.93 million | Fiscal year 2023: $8.31 million | Fiscal year 2022: -$14.93 million | Fiscal year 2021: -$27.58 million | Fiscal year 2020: -$6.52 million | Fiscal year 2019: -$18.28 million | Fiscal year 2018: -$26.46 million | Fiscal year 2017: -$83.44 million | Fiscal year 2016: -$29.37 million | Fiscal year 2015: $58.04 million | Fiscal year 2014: -$29.94 million | Fiscal year 2013: -$27.79 million | Fiscal year 2012: -$11.62 million | Fiscal year 2011: -$36.53 million | Fiscal year 2010: -$29.00 million | Fiscal year 2009: -$31.44 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026